Sonde Health has signed a multi-year agreement with Koye Pharma, a specialty pharma organisation focussed on the Indian pharma market, to develop a new vocal biomarker detection and monitoring capability for Chronic Obstructive Pulmonary Disease (COPD) in India. This deal represents Sonde’s first partnership with a pharma company, the companies said in a joint statement.
As part of this arrangement, Koye will leverage Sonde’s vocal biomarker development (VBD) platform, expanding upon its already existing respiratory responsive vocal biomarker, to create an entirely novel vocal biomarker for COPD in India. This will allow Koye to develop solutions that help track and treat respiratory health in COPD patients using their voice, the statement added.
It also informed that Sonde Health has previously developed and commercialised vocal biomarker technology to detect and monitor respiratory impairment. In early 2022, the company partnered with GN Group, a leading global manufacturer of hearing instruments and audiological diagnostics equipment and headsets, to create vocal biomarker technology to detect mild cognitive impairment.
Sonde Health and Koye Pharma plan to explore developing more vocal biomarkers during their multi-year arrangement, concluded the statement.
I love your great blog, thanks a lot and keep up the good work.